Introduction
============

Sepsis is a severe disease with poor clinical as economical outcomes and a high mortality \[[@B1]-[@B3]\]. Moreover sepsis treatment does often not adhere to practice recommendations \[[@B4]\].

PCT is a well proven test for detection of bacterial infections and to determine start and end of antibiotic therapy in various settings \[[@B5]-[@B9]\]. Using PCT-based algorithms to monitor and manage antibiotic treatment saves ABD and ICUD as well as cost for antibiotics (by the effect of allowing an early de-escalation strategy). This has been proven in PCT-related RCTs and verified in meta-analyses and reviews \[[@B7],[@B8],[@B10],[@B11]\].

The cost-efficiency of using PCT to reduce cost of antibiotic treatment was also shown \[[@B12],[@B13]\].

In Germany hospitals are reimbursed by Diagnoses Related Groups (DRG) determined payments. Due to the nature of DRG-based reimbursement systems clinical and economical optimization should focus on the reduction of LOS especially ICUD \[[@B14],[@B15]\]. In many hospitals cost-saving efforts are centered on single areas like medication cost, cutting staff expenses or other without calculating the effects on the complete treatment process.

However, so far no publications are available which investigate the economic effect of the possible savings by using PCT-based treatment algorithms in a DRG-reimbursement setting.

We conducted a study to determine possible savings in medication costs and costs for ICU-treatment using DRG data and favourable effects of a PCT-based treatment algorithm in sepsis patients.

Materials and methods
=====================

We retrieved patient level DRG routine data from 16 hospitals in Germany. All patients were treated in 2010. The German National minimal basic datasets (MDBS) contains episode data (admission and discharge date, ICUD) and diagnoses (one PDX and up to 50 SDX).

ICUD are reported if the patient is treated in a specialised intensive-care unit. From previous data analyses we know that there exists an amount of patients treated in intermediate care units.

We developed an algorithm to detect sepsis patients by using the various ICD-10 codes and examining PDX and SDX of all patients. Once a sepsis code occurred the patients were flagged as \'Sepsis present\'. By using the ICUD provided from the hospitals we further determined whether the patient was treated on ICU or not. If so, we flagged the patients as \'ICU treated\'. Patients being on intermediate care units or small intensive care units without ICUD being present in the dataset we flagged as \'Non-ICU\'.

Existing reviews on PCT are often based on RCTs with varying sample structures without considering influences of the different sample structures. Although favourable outcomes are proven, we decided to calculate possible positive effects of a PCT-based algorithm by pooling data from RCTs which mainly deal with sepsis patients or at least had sepsis patient or bloodstream infections as subgroups. As ICUD and ABD are continuous variables we calculated weighted means according to the recommendations in the QUOROM statement \[[@B16]\].

Using the results from a recent review on PCT-based algorithms for the management of infections \[[@B7]\], we calculated an average utilization of 7 subsequent PCT-tests. The average cost for a PCT-test in Germany is € 25 (based on data from the vendor). This would reflect the application of an algorithm based on daily testing.

By using the German National costing manual, we estimated treatment costs for each patient as the hospitals did not deliver data from the German National Cost data collection. The Institute for the reimbursement system in hospitals - InEK provides national average costs for each German DRG. However these costs are strongly related to the LOS in hospitals and to the ICUD. Therefore we calculated costs for the patients by calculating the following cost proportions from the national average costs:

• ICU costs: the German average costs for one day of ICU treatment is app. € 1, 100 \[[@B3]\]. ICUD were multiplied with these costs

• LOS-related costs: Treatment on the regular ward (including intermediate care), the use of diagnostic departments and medication costs show a strong correlation to the LOS. We calculated a NLOS by subtracting the ICUD from the LOS. NLOS was multiplied with the LOS-related costs

• Therapy related costs: Each DRG contains costs for the main therapy in hospital like surgery or cardiologic interventions or anaesthesia. These costs were directly taken from the national cost averages for each DRG

Thus we were able to estimate patient individual costs dependent on the individual LOS and ICUD.

To calculate savings from applying the PCT-based algorithm on our populations we used the following assumptions:

• ICUD according to the pooled analyses can only be saved, if ICUD of the individual patient is at least one day longer than the estimated savings. Thus we avoided implausible results if patients had e.g. only one ICUD. As medication costs (including antibiotics) are already part of the cost calculation for one day of ICU treatment, we did not reduce medication costs in patients with ICUD present

• For all patients without ICUD present, we only calculated savings from shorter ABD. As data on intermediate care stays were not available, we chose this conservative approach in order to avoid overestimation of possible savings. Costs for antibiotic treatment in sepsis vary \[[@B3],[@B7],[@B13]\]. We chose to build a flexible range for these costs in our simulation model with average daily costs of € 66

The simulation model was built by including all patients detected as \'sepsis\' patients in the following (simplified) equation:

$$\begin{matrix}
{Cost\left( {PCT - based\; algorithm} \right) = original\; costs - costs} \\
{respecting\; savings + costs\; for\; additional\; PCT - testing.} \\
 \\
\end{matrix}$$

PCT-tests are already performed in most of the hospitals in this study but the utilization of the results in terms of making treatment decisions is low \[[@B4]\]. Therefore we decided not to take the current cost in account. This is - again - a conservative estimate, as hospitals that will start using an optimized treatment algorithm will most likely not produce costs of 7 extra tests but only the incremental average increase.

Results
=======

We collected data from several RCTs to determine possible favourable effects of PCT \[[@B9],[@B17]-[@B21]\]. The studies had the following results as shown in Table [1](#T1){ref-type="table"}.

  Author         Year   Patient population           Cases   Cases   ABD    ABD    ICUD   ICUD
  -------------- ------ ---------------------------- ------- ------- ------ ------ ------ ------
  Nobre et.al.   2008   Sepsis                       31      37      6      10     3      5
  Hochreiter     2009   SIRS                         57      53      5.9    7.9    15.5   17.7
  Bouadma        2010   Various, only Sepsis used!   55      53      9.8    12.8   n.a.   n.a.
  Svoboda        2007   postoperative Sepsis         38      34      n.a.   n.a.   16.1   19.4
  Stolz          2009   VAP (Sepsis included)        51      50      7      15     n.a.   n.a.
  Schroeder      2009   Surgical sepsis patients     14      13      6.6    8.3    n.a.   n.a.

We included 6 studies. From the Boudma publication of the PRORATA trial we extracted the results from sepsis patients as the trial contained several different infections. The publication from Stolz was based on ventilator-associated pneumonia. However a number of patients suffered from septic shock and/or bacteraemia. Moreover VAP is a severe bacterial infection on the ICU.

By pooling the results and calculated the weighted means as well as the weighted mean difference (WMD) of all trials we found the following results as basis for our simulation model (Table [2](#T2){ref-type="table"}).

                         ABD (5 studies)   ICUD (3 studies)          
  ---------------------- ----------------- ------------------ ------ ------
  Weighted Mean (days)   7.3               11.3               12.6   14.4
  WMD (days)             -4.0              -1.8                      

For the further calculation we used possible reduction in ABD of -4 days and a possible reduction in ICUD of -1.8 days.

The weighted mean for days of antibiotic therapy (ABD) was 7.3 in the pooled PCT-groups. Therefore we took the assumption that 8 PCT-test will be a realistic frequency. We developed an algorithm based on recent reviews and publications on PCT in sepsis patients \[[@B7],[@B13]\]. The findings from Charles et.al. strongly recommend daily PCT-testing as the Delta between day 2 and day 3 shows a significant correlation to adequate versus inadequate ABX \[[@B5]\]. Figure [1](#F1){ref-type="fig"} shows our recommended algorithm.

![](2047-783X-16-12-543-1){#F1}

We received 278, 264 datasets. In 3, 263 episodes sepsis was detected and the cases were included in our analysis. 2, 968 cases had at least one day of ICU stay (Range: 1-32). 1, 312 cases had at least 3 ICUD and were included in the calculation of the savings in the ICU. 268 out of 295 Non-ICU cases had a total Los that was at least 6 days and therefore the possible savings of 4 ABD were applied.

The Figure [2](#F2){ref-type="fig"} gives an overview of the patient selection. Table [3](#T3){ref-type="table"} shows the overall financial results after applying the simulation model.
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                                            ICU - Cases         Non-ICU Cases
  ----------------------------------------- ------------------- ---------------
  n =                                       1, 312              268
  ALOS                                      27.7 ± 25.7         17.5 ± 14.6
  National ALOS                             22.7                10.3
  Avg. ICUD                                 8.8 ± 8.7           0
  **Costs before applying PCT-Algorithm**                       
  Total Costs (€)                           24, 700, 000        1, 667, 000
  ICU-Costs (€)                             12, 788, 000        0
  Medication Costs (€)                      2, 205, 000         266, 499
  Laboratory Costs (€)                      2, 140, 000         110, 000
  **Costs after applying PCT-Algorithm**                        
  Total Costs (€)                           23, 537, 000        1, 630, 488
  ICU-Costs (€)                             11, 314, 000        0
  Medication Costs (€)                      1, 877, 000         176, 387
  Laboratory Costs (€)                      2, 381, 000         163, 600
  **Total Savings (€)**                     **- 1, 163, 000**   **-36, 512**

Introducing the suggested algorithm for PCT-based ABX saves € 1, 199, 512 in our sample population. As ICU-costs are tremendous, the savings achieved by shortening ICUD outweigh the savings achieved through reduction of ABD. However, even ABD-reduction covers the extra-costs for daily PCT-testing. As most hospitals in our sample do already measure PCT but not following strict algorithms the savings are even higher because we assumed all 8 PCT-tests will cause extra cost.

In average € 886.4 can be saved, when patients need intensive care and € 136.2 can be saved per case when patients are Non-ICU.

Discussion
==========

We found that our results about reduction of ABX-costs are consistent with the results in other studies. Heyland et.al. assumed a reduction of 2 ABD with avg. daily ABX-costs of Can\$148.26 using a regimen of avg. 6 PCT-test which cost Can\$49.42 \[[@B13]\]. All other published results did not explicitly refer to ABX costs but to the reduction of ABD. A reduction of ICUD most certainly leads to substantial savings, as the cost per day are much higher than the costs for PCT-testing. However in the real life a cost reduction may only occur in terms of variable costs, because if less ICUD are needed to treat sepsis patients when applying the PCT-based algorithm, the fixed costs in the ICU remain untouched. On the other hand in most German ICUs there\'s a constant shortage of available beds and various strategies are carried out to meet the demand \[[@B22]-[@B24]\]. Therefore the full daily ICU costs can be taken in account assuming that the bed is used by a new patient and a constant utilization of the ICU is maintained even if the optimized therapy strategies lead to shorter ICUD in sepsis.

The results shown in this study are based on predictive modelling. We already remarked that modelling is only part of the story \[[@B15]\]. From our point of view each model has to be proven in clinical reality. Knowing the obstacles as low adaption rate of practice guidelines \[[@B4]\], this is a challenging task. We plan to implement the algorithm described in this paper in 5-10 hospitals in 2012 and measure the effects on ICUD and ABD in the clinical reality.

Conclusion
==========

By using a standardized algorithm for PCT-guided ABX-Therapy and assuming that the effects of ABD and ICUD derived from former studies will apply to the selected patient population the use of PCT is highly cost-effective!

ABD and ICUD reductions results in savings of up to € 1, 199, 512 or € 886.4 in average for ICU-patients and € 136.2 for Non-ICU patients.

As shown in many other trials the clinical outcome is not negatively affected if ABX is shortened using PCT-based algorithms.

The model we developed will be used for further investigations. After implementation in clinical reality direct measurement of the effects will be possible.
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Abbreviations
=============

ABD: Days of antibiotic treatment; ABX: Antibiotic Therapy; ALOS: Average length of stay in a given DRG, basis for determining whether a patient causes more costs than reimbursement; CW: Cost-weight of a given DRG, directly related to clinical and economical \"severity\" (re-source consumption); DRG: Diagnoses related groups, systems to classify patients based on their resource consumptions; HMV: Hours of mechanical ventilation; ICD: International Classification of Diseases; ICD-10: ICD, Revision 10; ICU: Intensive care unit; ICUD: treatment days on an intensive care unit; LOS: Length of stay in hospital; NLOS: Length of stay on normal ward; PCT: Procalcitonin laboratory test - a biomarker; PDX: Primary diagnosis (in ICd-10); RCT: Randomized control trial; SDX: Secondary diagnosis (in ICd-10); VAP: Ventilator-associated pneumonia.
